Aging Is the Primary Risk Factor for Chronic Disease
Aging is the dominant risk factor for nearly every major chronic disease, including cancer, Alzheimer’s disease, diabetes, osteoarthritis, macular degeneration, sarcopenia, and many others. Gerotherapeutics seek to intervene upstream—at the core biological processes that drive age‑related decline—offering the possibility of extending healthspan and reducing the global burden of disease.
A New Therapeutic Paradigm: Information‑Encoded Peptides
Traditional pharmaceuticals typically function by binding a specific receptor or modulating a defined biochemical pathway. In contrast, the MitoXcel™ Platform Technology, discovered and owned by SENOTHERAPEUTIX, Inc. (d/b/a GEROTHERAPEUTIX, Inc.), introduces a fundamentally new class of gerotherapeutics whose activity is governed by the biophysical informational content of their amino acid sequences.
Just as DNA encodes genetic information through nucleotide order, MitoXcel™ geropeptides encode functional information through sequence‑defined charge distribution, amphipathicity, and structural motifs. These parameters determine mitochondrial localization, interactions with the Inner Mitochondrial Membrane and associated protein members of the Electron Transport Chain (ETC), and downstream bioactivity.
MitoXcel™ Technology is therefore not a single drug, but a design framework—a family of peptides that must meet a precise set of computationally derived design rules. Only sequences that satisfy the MitoXcel™ blueprint qualify, ensuring reproducible performance and consistent mechanistic activity across candidates.
Targeting a Universal Feature of Aging: Declining Mitochondrial Membrane Potential (ΔΨm)
Across all living organisms, aging is accompanied by a predictable decline in mitochondrial membrane potential (MMP, ΔΨm). This bioenergetic deterioration precedes and drives impaired ATP production, metabolic instability, and the transition into senescence.
MitoXcel™ geropeptides are the first information‑encoded therapeutics explicitly engineered to recognize and exploit this aging‑specific energetic signature. Senescent cells exhibit markedly lower ΔΨm than healthy cells, providing a naturally occurring selectivity filter.
By targeting this biophysical vulnerability, MitoXcel™ geropeptides initiate two complementary mitochondrial‑mediated mechanisms:
Mechanism 1 — the rapid return of mitochondrial function in aging cells back to their younger, more efficient phenotype.
Mechanism 2 — which steadily and profoundly eliminates senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects, with no apparent side effects.
A True Gerotherapeutic Approach
Unlike disease‑specific drugs, MitoXcel™ geropeptides do not target individual pathologies. Instead, it intervenes at a root cause of aging—mitochondrial dysfunction—and allows downstream phenotypic improvements (reduced fat mass, increased muscle mass, enhanced tissue function, and others) to emerge naturally from restored cellular energetics and reduced systemic inflammation, a direct consequence of reduced senescent cell burden.
By encoding therapeutic function directly into amino acid sequence architecture and targeting a universal signature of aging biology, MitoXcel™ Technology represents a new category of medicine: information‑based gerotherapeutics.
The First Context-Dependent Gerotherapeutic
Eos SENOLYTIX’s lead clinical candidate MitoXcel™ geropeptide, PTC-2105, is unique in the obesity space in that it is a homeostatically adaptive therapeutic. It restores physiological balance towards its healthy set point rather than pushing biology in one direction (see the bottom of the Eos SENOLYTIX MitoXcel Technology page).
Our Origin and Family of Companies
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc., which was registered in Texas as d/b/a GEROTHERAPEUTIX, Inc. in 2025: (1) Eos SENOLYTIX, a longevity company developing novel MitoXcel™ geropeptide therapeutics to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel MitoXcel™ oncopeptides to treat cancer via this same novel target as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them, and our MitoXcel™ Technology website, that explains the remarkable technology driving them!
Powered by MitoXcel™ Technology
Eos SENOLYTIX’s PTC-2105, PTC-2107, and PTC-2113, Perseus SENOLYTIX’s PTC-2109, PTC-2110, PTC-2117 and PTC-2128 and Ponce Aurora’s PTC-2111, PTC-2116, PTC-2119 and PTC-2132 are all powered by MitoXcel™ Technology
Eos SENOLYTIX™, Perseus SENOLYTIX™, Phoenix SENOLYTIX™ and Ponce Aurora™ are affiliates of SENOTHERAPEUTIX, Inc., d/b/a GEROTHERAPEUTIX, Inc. Visit our affiliate Companies to learn more about them!
